BRAF+

Questions discussed in this category

If a BRAF-mutated melanoma patient developed metastatic disease progression on adjuvant anti-PD-1 monotherapy, do you recommend switching to BRAF/MEK targeted therapy or combination nivolumab/ipilimumab?

4 Answers available

What is your preferred first-line treatment for metastatic melanoma in a patient with a class 2/non-V600 BRAF mutation?

4 Answers available

What is your approach to a patient with an EGFR exon 19 mutated NSCLC who develops progression on osimertinib and repeat biopsy demonstrates the EGFR exon 19 mutation and a new BRAF V600E mutation?

1 Answer available

What is your preferred adjuvant systemic treatment for resected stage IV melanoma with a BRAF mutation?

Based on available results from the IMMUNED trial, which evaluated the role of adjuvant nivolumab/ipilimumab or nivolumab monotherapy vs placebo in re...

2 Answers available

How would you approach metastatic NSCLC (adenocarcinoma without brain mets) with PD-L1 >50% and BRAF V600E driver mutation?

2 Answers available

Do you recommend using BRAFV600E mutation status to risk stratify treatment for a pediatric patient with langerhans cell histiocytosis?

1 Answer available

For patients with BRAF V600E positive lung cancer and recent PE/DVT, is there any contraindication to BRAF/MEK inhibitor therapy?

Would you hold treatment for patients who develop PE/DVT while on BRAF-directed therapy?

1 Answer available

Do you recommend using cell-free BRAFV600E to track response to therapy in pediatric patients with langerhans cell histiocytosis?

0 Answers available

Would you discontinue dabrafenib/trametinib in a patient with BRAF mutant metastatic lung cancer if you see mild cardiomyopathy which could be related to the drugs?

Patient does not want chemo but is tolerating these well otherwise.

1 Answer available

Papers discussed in this category

J. Pediatr., 2014 Oct 21

Differentiating skin-limited and multisystem Langerhans cell histiocytosis.

The New England journal of medicine, 2014-11-13

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

Lancet Oncol., 2017 Sep 11

Dabrafenib plus trametinib in patients with previously untreated BRAF-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

The New England journal of medicine, 2012-11-01

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

J BUON,

Chromosome 7 deregulation in non-small cell lung carcinoma molecular landscape.

Br J Cancer, 2019 Sep 30

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.

The New England journal of medicine, 2018-08-23

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

J. Clin. Oncol., 2019 Feb 27

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.

Lancet Oncol., 2018 Mar 27

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.

N Engl J Med, 2019 Sep 28

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2013-03-01

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

J Clin Oncol, 2022 Sep 27

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Sep 01

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.

Nature medicine, 2023 Aug 17

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.

Journal for immunotherapy of cancer, 2023 Mar

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors.

BRAF+

Questions discussed in this category

Papers discussed in this category

Related Topics